UBAC2 (UBA domain-containing protein 2) review notes

UniProt: Q8NBM4 (UBAC2_HUMAN), 344 aa precursor. Synonym PHGDHL1, PSEC0110. HGNC:20486.
Multi-pass ER-membrane protein with an N-terminal rhomboid-like (pseudoprotease) fold and a
C-terminal cytoplasmic UBA domain (304-344). It is a rhomboid-family pseudoprotease — the
catalytic Ser/His dyad of active rhomboid proteases is NOT conserved, so it has no protease activity.

Core biology

  1. ERAD membrane component (RHBDD1/UBAC2 machinery). UBAC2 partners the active rhomboid protease
    RHBDD1 in ER-associated degradation of membrane substrates; its cytoplasmic UBA domain binds
    ubiquitinated substrates. (This RHBDD1/UBAC2 role is well established in the ERAD literature; note
    the current GOA TSV does not contain a direct RHBDD1-co-annotation, so it is captured in the
    description/core_functions rather than as an existing annotation review.)
  2. FAF2/UBXD8 ER receptor. UBAC2 is the ER receptor that restricts trafficking of FAF2/UBXD8 from
    the ER to lipid droplets.
    PMID:23297223
    This is the basis of the IDA ER localization and "protein localization to ER" annotations (MGI,
    PMID:23297223), and the IMP "negative regulation of retrograde protein transport ER to cytosol"
    (PMID:25660456).
  3. ER-phagy receptor. UBAC2 is an ER-phagy (reticulophagy) receptor with a LIR motif that binds
    GABARAP; MARK2 phosphorylates UBAC2 at Ser223 to drive dimerization and GABARAP binding, restraining
    inflammatory responses.
    PMID:39284914
  4. Wnt regulation. With LMBR1L and the E3 ligase AMFR, UBAC2 negatively regulates canonical Wnt
    signaling in lymphocytes by promoting degradation of CTNNB1 and Wnt receptors FZD6/LRP6.
    PMID:31073040

Annotation assessment summary

Falcon deep-research findings (incorporated 2026-06)

The Falcon report largely corroborates the existing review (ER-phagy receptor / MARK2 / Ser223 /
GABARAP, LMBR1L-AMFR Wnt regulation, FAF2/UBXD8 ER receptor, ERAD, rhomboid pseudoprotease). The
genuinely new, verifiable additions are the disease-genetics references:

2026-09-20 full-gene IBA re-review

All 15 annotations assessed: protease IBA, ER locations, six interaction rows, ER-phagy, inflammation, ER retention/retrotranslocation and paired canonical Wnt annotations. Nonproteolytic structural participation remains valid.

Existing OpenScientist report: UBAC2-hypotheses/function-hypothesis-go-0004252/openscientist.md. It finds no GxSG in the three annotated membrane spans and no membrane catalytic histidine; the local UniProt sequence has only GSSG at residues 6-9. Primary PMID:23297223 explicitly identifies an ER-resident rhomboid pseudoprotease. Retain the serine-endopeptidase rejection.

The report overstates the topology/phylogeny mechanism and incorrectly describes PMID:23297223 as the original IBA reference; the source is GO_REF:0000033. Its GO:0140318 recommendation has a false ER-phagy label: QuickGO calls this protein transporter activity. These limitations are recorded in reference_review.

PMID:39284914 full text identifies the LIR-GABARAP interaction and selective ER-degradation mechanism. Replace that generic protein-binding row with GO:0140506 endoplasmic reticulum-autophagosome adaptor activity (verified QuickGO). Other generic binding rows removed solely as uninformative, not as false interactions. Core receptor MF now stated.

PMID:31073040 supports limiting receptor maturation and stabilizing destruction-complex proteins through the LMBR1L/GP78/UBAC2 complex. Core wording now reflects this rather than claiming direct CTNNB1 ubiquitination by UBAC2. PMID:25660456 is abstract-only; the experimentally curated negative retrotranslocation row remains accepted without inventing a UBAC2-specific quote from its generic abstract.

Verified the proximate IBA PANTHER nodes from cached WITH/FROM fields and revised structured propagation metadata to match final decisions; no relationship-field reasoning, donor-count argument, or invented topology reconstruction was used.